The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N′-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.
                            本公开提供了(R)-
3,5-二甲基苯甲酸 N-(1-叔丁基-丁基)-N′-(2-乙基-3-甲氧基-苯甲酰基)-酰
肼(化合物 1)或(S)-
3,5-二甲基苯甲酸 N-(1-叔丁基-丁基)-N′-(2-乙基-3-甲氧基-苯甲酰基)-酰
肼(化合物 2)的结晶多晶型和无定形型。本公开进一步提供了包含化合物1或化合物2的结晶多晶型和无定形型以及赋形剂的组合物,制造化合物1或化合物2的结晶多晶型或无定形型的方法,以及使用化合物1或化合物2的结晶多晶型或无定形型调节细胞或受试者中
基因表达的方法。